Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2001-03-28
2003-07-01
Jarvis, William R. A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S345000, C514S350000, C514S351000
Reexamination Certificate
active
06586414
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a method of treating a cerebrovascular disease, including stroke. A method of treating a cerebrovascular disease includes administering pyridoxal-5′-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or a pharmaceutical composition thereof.
BACKGROUND
Cerebrovascular disease includes any abnormality of the brain resulting from a pathologic process of a blood vessel. A pathologic process of a blood vessel includes any one or more of the following: an occlusion of a blood vessel lumen by thrombus or embolus, a rupture of a blood vessel, an altered permeability of a blood-vessel wall, and increased viscosity or other change in the quality of blood.
Cerebrovascular disease is typically readily diagnosable because of how it manifests. Cerebrovascular disease typically manifests as a stroke. A stroke can be characterized as a sudden nonconvulsive, focal neurologic deficit. That is, stroke can be characterized as the death of brain tissue that results from lack of blood flow and insufficient oxygen to the brain. After heart disease and cancer, stroke is the leading cause of death in the United States. In the United States, there are approximately 500,000 cases of stroke annually. And these 500,000 cases give rise to about 175,000 fatalities.
A stroke can be ischemic or hemorrhagic. In an ischemic stroke, the blood supply to part of the brain is reduced or terminated either by a blood clot that blocks a blood vessel or by atherosclerosis. Reducing or terminating blood flow to the brain is known as cerebral ischemia. Cerebral ischemia can last for seconds to minutes, and when cerebral ischemia occurs for more than a few minutes, infarction of brain tissue results. A blood vessel can be blocked by a blood clot that arises from thrombus or embolus. Yet cerebral ischemia can also arise from the failure of circulation and hypotension from severe and prolonged cardiac decompensation or shock.
In a hemorrhagic stroke, the brain is damaged by a blood vessel bursting, which prevents normal blood flow and allows blood to leak into an area of the brain. In some instances, the blood leaks from a small artery. When blood leaks into the brain, a hematoma is formed in the brain and blood can spread into ventricles and subarachnoid space.
In cerebral hemorrhage, blood leaks from the vessel (usually a small artery) directly into the brain forming a hematoma, and the blood spreads into the ventricles and subarachnoid space. The hematoma can cause physical disruption of the brain tissue and pressure on the surrounding brain areas. When the blood leakage stops, the hematoma can slowly disintegrate and be absorbed over a period of weeks and months.
Several factors, including hypertension, heart disease, atrial fibrillation, diabetes mellitus, cigarette smoking of long duration, hyperlipidemia, use of birth control pills, and systemic diseases associated with a hypercoagulable state, are known to increase the susceptibility of individuals to stroke.
It is desirable to develop treatments for cerebrovascular disease, including cerebral hemorrhage, cerebral ischemia, ischemic stroke, hemorrhagic stroke, and ischemic reperfusion injury arising from reintroduction of blood flow following cerebral ischemia or ischemic stroke.
SUMMARY OF THE INVENTION
The invention includes methods for treating cerebrovascular disease. In one aspect, the invention includes a method for treating cerebral ischemia, cerebral hemorrhage, ischemic stroke, hemorrhagic stroke, or ischemic reperfusion injury resulting from reintroduction of blood flow following cerebral ischemia or ischemic stroke. A method of the invention includes administering one or more therapeutic compounds such as pyridoxal-5′-phosphate, pyridoxine, pyridoxal, and pyridoxamine.
In another aspect, the invention is directed to a method for treating cerebral ischemia, cerebral hemorrhage, ischemic stroke, hemorrhagic stroke, or ischemic reperfusion injury resulting from reintroduction of blood flow following cerebral ischemia or ischemic stroke by administering one or more therapeutic compounds such as 3-acylated analogues of pyridoxal, 3-acylated analogue of pyridoxal-4,5-aminal, or a pharmaceutical composition thereof.
In another aspect, the invention is directed to a method for treating cerebral ischemia, cerebral hemorrhage, ischemic stroke, hemorrhagic stroke, or ischemic reperfusion injury resulting from reintroduction of blood flow following cerebral ischemia or ischemic stroke by administering one or more therapeutic compounds such as pyridoxine phosphonate analogues, or a pharmaceutical composition thereof.
In another aspect, the invention is directed to pharmaceutical compositions that include a pharmaceutically acceptable carrier and a therapeutically effective amount of a therapeutic compound selected from pyridoxal-5′-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or phamaceutically acceptable salts thereof, for treating a cerebral vascular disease.
REFERENCES:
patent: 3206463 (1965-09-01), Baetz
patent: 3910921 (1975-10-01), Esanu
patent: 3987177 (1976-10-01), Giudicelli et al.
patent: 4032534 (1977-06-01), Chodkiewicz
patent: 4036844 (1977-07-01), Thorne et al.
patent: 4053607 (1977-10-01), Thorne et al.
patent: 4137316 (1979-01-01), Esanu
patent: 4167562 (1979-09-01), Evers
patent: 4361570 (1982-11-01), Fici
patent: 4369172 (1983-01-01), Schor et al.
patent: 4374841 (1983-02-01), Descamps et al.
patent: 4515771 (1985-05-01), Fine
patent: 4567179 (1986-01-01), Lombardino
patent: 4569938 (1986-02-01), Esanu
patent: 4569939 (1986-02-01), Esanu
patent: 4581363 (1986-04-01), Esanu
patent: 4605741 (1986-08-01), Zagnoli et al.
patent: 4730042 (1988-03-01), Hege et al.
patent: 4735950 (1988-04-01), Esanu
patent: 4735956 (1988-04-01), Baldwin et al.
patent: 4837239 (1989-06-01), Benjamin et al.
patent: 4843071 (1989-06-01), Hohenwarter
patent: 4962121 (1990-10-01), Hamberger et al.
patent: 5001115 (1991-03-01), Sloan
patent: 5053396 (1991-10-01), Blass
patent: 5118505 (1992-06-01), Költringer
patent: 5130324 (1992-07-01), Ulrich et al.
patent: 5132115 (1992-07-01), Wolter et al.
patent: 5210083 (1993-05-01), Pfirrmann
patent: 5213813 (1993-05-01), Kornecki et al.
patent: 5254557 (1993-10-01), Buckle et al.
patent: 5254572 (1993-10-01), Serfontein
patent: 5272165 (1993-12-01), Ulrich et al.
patent: 5278154 (1994-01-01), Lacoste et al.
patent: 5288716 (1994-02-01), Speck
patent: 5326757 (1994-07-01), Demopoulos
patent: 5328453 (1994-07-01), Sibalis
patent: 5372999 (1994-12-01), Schneider et al.
patent: 5385937 (1995-01-01), Stamler et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5441972 (1995-08-01), Ogata et al.
patent: 5504090 (1996-04-01), Neely
patent: 5563126 (1996-10-01), Allen et al.
patent: 5569459 (1996-10-01), Shlyankevich
patent: 5569648 (1996-10-01), Lewis et al.
patent: 5631271 (1997-05-01), Serfontein
patent: 5633228 (1997-05-01), Lewis et al.
patent: 5648335 (1997-07-01), Lewis et al.
patent: 5728684 (1998-03-01), Cheng et al.
patent: 5733884 (1998-03-01), Neely
patent: 5770215 (1998-06-01), Moshyedi
patent: 5795873 (1998-08-01), Allen
patent: 5804163 (1998-09-01), Gibby et al.
patent: 5804594 (1998-09-01), Murad
patent: 5833998 (1998-11-01), Biedermann et al.
patent: 5834446 (1998-11-01), Dow et al.
patent: 5840685 (1998-11-01), Fujii et al.
patent: 5847008 (1998-12-01), Doebbler et al.
patent: 5858017 (1999-01-01), Demopulos et al.
patent: 5859051 (1999-01-01), Adams et al.
patent: 5874420 (1999-02-01), Pelleg
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5888514 (1999-03-01), Weisman
patent: 5944020 (1999-08-01), Markov et al.
patent: 6043259 (2000-03-01), Dhalla et al.
patent: 6310093 (2001-10-01), Newcomb
patent: 831350 (1976-01-01), None
patent: 863754 (1978-05-01), None
patent: 561 183 (1975-04-01), None
patent: 24 61 742 (1976-
Haque Wasimul
Sethi Rajat
Jarvis William R. A.
Medicure International Inc.
Merchant & Gould P.C.
LandOfFree
Treatment of cerebrovascular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of cerebrovascular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cerebrovascular disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3052289